In this issue:
- Acquired genomic alterations on first-line chemotherapy with cetuximab
- Global burden of CRC in 2020 and 2040
- Galunisertib + neoadjuvant chemoradiotherapy for locally advanced rectal cancer
- FOLFOXIRI + bevacizumab and atezolizumab for metastatic CRC
- Modified FOLFOXIRI + panitumumab for metastatic CRC
- Fluoropyrimidine + bevacizumab with irinotecan escalation for metastatic CRC
- FOLFOX + panitumumab after resection of CRC liver metastases
- Apatinib-chemotherapy combinations for advanced CRC
- Personalized total neoadjuvant therapy for advanced rectal cancer
- FOLFIRI + cetuximab vs bevacizumab for RAS wild-type metastatic CRC
Please login below to download this issue (PDF)